CASP3 and neoplasm: Further investigation of the mechanisms of the antitumor activity of lapatinib plus foretinib combination therapy, compared to lapatinib or foretinib monotherapy, by immunohistochemical analyses of tumor tissues revealed a significantly reduced Ki67-proliferative index, and also a significantly enhanced cleaved caspase 3-apoptosis index.